Protox Therapeutics Inc. announced today that
the Investigational New Drug (IND) application for PRX302, the Company's lead
product for the treatment of recurrent localized prostate cancer, has been
cleared by the US Food and Drug Administration (FDA). As reported previously,
the IND application was filed in December, 2005 and its clearance means that
the Company may now proceed with the initiation of its Phase I clinical trial.
PRX302 is the first of a novel class of targeted prodrugs based on the
Company's PORxin(TM) platform. It is a therapeutic pore-forming toxin designed
to be activated by prostate specific antigen (PSA), an enzyme which is
produced and is active only in the prostate.
